Raymond James set a price target of $69 for NASDAQ:BBIO, indicating a potential increase of about 9.17%.BBIO announced positive interim results from its Phase III FORTIFY trial for Limb-Girdle Muscular Dystrophy Type 2I/R9, boosting investor confidence.The company's stock price rose to $63.56, marking a 17.14% increase and reflecting strong market confidence in BBIO's future.BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company focused on developing treatments for genetic diseases. The company is ...